Why the study?
Does short-term combination therapy with ticagrelor and PPIs or H2RA reduce gastrointestinal bleeding in patients with acute STEMI who underwent emergency PCI?
Does short-term combination therapy with ticagrelor and PPIs or H2RA reduce gastrointestinal bleeding in patients with acute STEMI who underwent emergency PCI?
Short-term combination of ticagrelor and PPIs reduces gastrointestinal bleeding without increasing ischemic events in STEMI patients after emergency PCI.
Answers are grounded in this paper and cite their sources.
PPI co-therapy was associated with lower GI bleeding in ticagrelor-treated STEMI; hypothesis-generating and requires randomized confirmation before practice change.
), myocardial necrosis biomarker (creatine kinase isoenzyme-MB and cardiac troponin I) levels, brain natriuretic peptide levels, the incidence of ischemic end point events, and the incidence of other tissue and organ bleeding events among the four groups. The incidence of gastrointestinal (GI) bleeding events in the proton pump-inhibitor (PPI) group was significantly lower than that in the control group, whereas in the H2 receptor antagonist (H2RA) group it was not significantly different from the control group. The short-term combination therapy with ticagrelor and PPIs or H2RA is safe and effective in patients with acute STEMI after PCI. In addition, the PPIs combined with ticagrelor could reduce the incidence of GI bleeding events without increasing the incidence of ischemic events.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: